Piramal Pharma Limited announced its Q2 and H1 FY26 results, reporting revenue of ₹2,044 crore for Q2 and ₹3,977 crore for H1. Revenue was affected by inventory destocking in a large CDMO order. Despite revenue dips, cost optimization partially offset the impact on EBITDA. The company anticipates better performance, driven by increased biopharma funding and strong interest in onshore offerings.
Financial Performance Overview
Piramal Pharma Limited (NSE: PPLPHARMA | BSE: 543635) announced its consolidated results for Q2 and H1 FY26, ended September 30, 2025. Key financial highlights include:
- Revenue from Operations: ₹2,044 crore for Q2 FY26 (down 9% YoY) and ₹3,977 crore for H1 FY26 (down 5% YoY).
- EBITDA: ₹224 crore for Q2 FY26 (down 44% YoY) and ₹389 crore for H1 FY26 (down 38% YoY).
- PAT: ₹(99) crore for Q2 FY26 and ₹(181) crore for H1 FY26.
Segmental Performance
The company’s performance across its key segments was as follows:
- CDMO: Revenue decreased by 21% YoY in Q2 and 14% YoY in H1, impacted by inventory destocking in a large on-patent commercial product.
- Complex Hospital Generics (CHG): Revenue saw minimal change, up by 0% YoY in Q2 and 1% YoY in H1.
- Piramal Consumer Healthcare (PCH): Showed growth of 15% YoY in both Q2 and H1.
Key Business Highlights
CDMO Business
- Impacted by inventory destocking and inconsistent recovery in US biopharma funding.
- Seeing early signs of improvement with funding uptick in September and October 2025.
- Focus on cost optimization and operational excellence.
- Multi-million-dollar joint investment at Sellersville site (US) for commercial manufacturing of Obicetrapib and Ezetimibe.
Complex Hospital Generics (CHG)
- Maintained leadership position in the US Sevoflurane market.
- Intrathecal therapy sales impacted by temporary supply challenges.
Piramal Consumer Healthcare (PCH)
- Power Brands continued strong growth, contributing to 51% of total PCH sales.
- E-commerce sales grew at over 40% YoY.
Other Updates
- Net-Debt reduced by ₹228 crore compared to FY25.
- Released its 4th Annual Sustainability Report for FY25.
Source: BSE